BioMed Realty Trust BMR reported 4Q10 diluted FFO per share of $0.30, “which is above our estimate and consensus of $0.28,” Jefferies reports.
“BioMed's focus on the life science industry is a positive given the secular growth drivers of an aging population and demand for healthcare,” Jefferies writes. “However, we would like to see improved leasing in the company's weaker markets to get more constructive on the stock.”
BioMed Realty Trust currently trades at $18.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in